OR WAIT null SECS
Executive Director of Interventional Cardiovascular Programs at Brigham and Women's discusses some research he took part in being presented at this year's conference.
While the ongoing coronavirus disease 2019 (COVID-19) pandemic has forced the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) to go virtual, it does not change the value of the data coming from this year’s meeting.
In lieu of in-person interviews from the conference floor, HCPLive® is conducting House Call video conferences with presenters and leading cardiologists in an effort to provide our audience with the same access to data they would normally receive through our coverage of the conference. In this special edition House Call, we spoke with Deepak Bhatt, MD, MPH, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and professor of Medicine at Harvard Medical School, for insights into data he was associated with from this year’s conference.
While time did not permit for discussion of the more than 2 dozen pieces of research Bhatt took part in from this year’s conference, the following conversation features topics including an analysis of a novel risk score for predicting venous thromboembolism, the impact of ticagrelor on major adverse limb events, and a discussion on the current state of LDL-C lowering.
The studies featured in this video—“PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE,” and “TICAGRELOR AND MAJOR ADVERSE LIMB EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS”—were published in JACC.